Skyhawk Therapeutics to Present Preclinical Data of SKY-1214 Combination Treatment in Hematologic Cancers at the 66th American Society of Hematology Annual Meeting

SKY-1214 demonstrates impressive synergistic anti-cancer activity in vivo and in vitro in combination with multiple commonly used and emergi

Skyhawk Therapeutics to Present Additional Positive Topline Data from Parts A and B of Phase 1 Clinical Trial of SKY-0515 at European Huntington's Disease Network and Enroll-HD 2024

The presentation highlights additional positive topline results from SAD/MAD study and preclinical data of SKY-0515, a novel small...

Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman

Skyhawk today announced the promotion of Clint Musil, former Chief Financial Officer of Skyhawk Therapeutics, to Chief Executive Officer and

Ipsen dives into $1.8B Skyhawk pact to fire up RNA modulator R&D

Ipsen has swooped on a $1.8 billion R&D opportunity, joining with Skyhawk Therapeutics for the chance to option two candidates that could...

Drugging RNA

Small molecules that target messenger RNA have therapeutic potential, but the field still lacks an unqualified success.

Bill Haney’s latest startup scores deal from Sanofi its newest Big Pharma partner, with $54M upfront

A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist.

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President

Skyhawk Therapeutics Expands Leadership Team, Appointing Elliot Ehrich MD as President and Graeme Smith PhD as SVP NonClinical Development

Skyhawk Therapeutics Presents Compelling Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

SKY-1214, an IND-ready first-in-class FANCL/FANCI RNA splicing modulator, demonstrates tumor growth inhibition and regression to undetectabl

Skyhawk Therapeutics Announces Positive Topline Results of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

Skyhawk’s SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose

Ipsen, Skyhawk ink deal worth up to $1.8B

Ipsen, Skyhawk Therapeutics pen neurological deal: Ipsen and Skyhawk plan to develop small molecules that can modulate RNA in a deal...

Skyhawk Has Advanced to Multiple Ascending Dose in it’s SKY-0515 Huntington’s Trial

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform.

Drugging RNA with Pills : Small Molecules for a Big Frontier

Can biotechnology startups turn what were once accidental discoveries into a purposeful way to hit hard-to-reach disease targets?

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates in

$40M up front: Skyhawk takes flight with Vertex deal

Skyhawk Therapeutics Inc., one of the early leaders in developing small-molecule drugs that target RNA, closed out the year with yet another

Skyhawk Therapeutics to Present Preclinical Data on SKY-1214 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium

SKY-1214, a first-in-class FANCL/FANCI RNA splicing modulator, demonstrated broad anti-cancer activity in multiple cancers, including...

Skyhawk Therapeutics Expands into State-of-the-Art Labs in its Basel, Switzerland Location

"Skyhawk has achieved tremendous scientific advances in our Basel Switzerland location so far," said Sergey Paushkin, CSO

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following...

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small

SKY-0515 is a small molecule RNA splicing modifier developed through the company’s novel SKYSTAR®

Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets

Companies to leverage Skyhawk’s proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to...

Bill Haney adds another $133M to Skyhawk’s coffers, as the RNA startup guns for the clinic

A few years after becoming one of the first major biotechs out to drug RNA with small molecules, serial entrepreneur and filmmaker Bill Hane